Investor Type | Firm |
Stages | Acquisition |
Investing | United Kingdom |
Investment Range | $2,530,000 - $2,530,000 |
Healthcare Capital Partners (HCP) is a London-based investment banking firm specializing in the healthcare and life sciences sectors. They cater to small and middle-market healthcare companies, providing comprehensive advisory services for sales and divestitures, shareholder restructuring, mergers and acquisitions, private placements, and debt refinancing. The firm’s investment activity spans both the US and Europe, focusing on facilitating value-enhancing transactions such as business and asset divestitures as well as private equity and venture capital fund raising. HCP’s notable strength lies in their trans-Atlantic team, comprised of seasoned professionals with extensive experience as senior members of European and US healthcare and life sciences companies. This gives them a competitive edge in advising clients on corporate or project strategy. Another distinctive aspect of HCP’s approach is their willingness to accept equity participation in lieu of cash for advisory fees, potentially taking on roles as shareholders and/or board members to continue providing financial and strategic advice post-transaction. HCP's expertise includes work in the pharmaceutical, medtech, life sciences, and healthcare services sectors, and their partners have completed over 100 transactions with a cumulative value exceeding $1 billion. A majority of their transactions have ranged between $10-100 million. With offices in London, Zurich, and Boston, HCP leverages international perspectives to structure deals that enhance corporate value, often maintaining active involvement and dialogue with clients even after deal completion. They highlight their commitment to customized project strategies that consider critical market, regulatory, and other considerations. Their transaction portfolio showcases a variety of deals, such as the secondary buy-out of Sebia, the sale of Renal Services to DaVita International, advisory for Boston Scientific in the sale of CathNet Sciences SA, and private placement assistance for companies like Cannaray and Santersus.